209 related articles for article (PubMed ID: 16318875)
21. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
Chino B; Nemoto T; Fujii C; Mizuno M
Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
[TBL] [Abstract][Full Text] [Related]
22. Maintenance ECT in treatment-resistant schizophrenia.
Chanpattana W
J Med Assoc Thai; 2000 Jun; 83(6):657-62. PubMed ID: 10932493
[TBL] [Abstract][Full Text] [Related]
23. Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis.
Carlsson R; Nyman H; Ganse G; Cullberg J
Acta Psychiatr Scand; 2006 Feb; 113(2):102-11. PubMed ID: 16423161
[TBL] [Abstract][Full Text] [Related]
24. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders.
Duncan JC; Rogers R
J Forensic Sci; 1998 Nov; 43(6):1133-7. PubMed ID: 9846389
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
26. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors.
Klingberg S; Schneider S; Wittorf A; Buchkremer G; Wiedemann G
Psychiatry Res; 2008 Nov; 161(2):225-34. PubMed ID: 18922582
[TBL] [Abstract][Full Text] [Related]
27. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.
Byerly M; Fisher R; Whatley K; Holland R; Varghese F; Carmody T; Magouirk B; Rush AJ
Psychiatry Res; 2005 Feb; 133(2-3):129-33. PubMed ID: 15740989
[TBL] [Abstract][Full Text] [Related]
28. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
29. Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia.
Aki H; Tomotake M; Kaneda Y; Iga J; Kinouchi S; Shibuya-Tayoshi S; Tayoshi SY; Motoki I; Moriguchi K; Sumitani S; Yamauchi K; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
Psychiatry Res; 2008 Feb; 158(1):19-25. PubMed ID: 18160137
[TBL] [Abstract][Full Text] [Related]
30. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
31. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
32. [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment].
Kühn KU; Quednow BB; Landen H; Riedel M; Thiel M
Fortschr Neurol Psychiatr; 2004 Jul; 72(7):397-403. PubMed ID: 15252753
[TBL] [Abstract][Full Text] [Related]
33. Adjusting the frequency of continuation and maintenance electroconvulsive therapy to prevent relapse of catatonic schizophrenia in middle-aged and elderly patients who are relapse-prone.
Suzuki K; Awata S; Takano T; Ebina Y; Shindo T; Harada N; Matsuoka H
Psychiatry Clin Neurosci; 2006 Aug; 60(4):486-92. PubMed ID: 16884452
[TBL] [Abstract][Full Text] [Related]
34. Shiatsu as an adjuvant therapy for schizophrenia: an open-label pilot study.
Lichtenberg P; Vass A; Ptaya H; Edelman S; Heresco-Levy U
Altern Ther Health Med; 2009; 15(5):44-6. PubMed ID: 19771930
[TBL] [Abstract][Full Text] [Related]
35. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome.
Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
J Clin Psychiatry; 1993 Feb; 54(2):59-62. PubMed ID: 8095259
[TBL] [Abstract][Full Text] [Related]
36. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
[TBL] [Abstract][Full Text] [Related]
37. Medication adherence and quality of life among Nigerian outpatients with schizophrenia.
Adelufosi AO; Adebowale TO; Abayomi O; Mosanya JT
Gen Hosp Psychiatry; 2012; 34(1):72-9. PubMed ID: 22036736
[TBL] [Abstract][Full Text] [Related]
38. Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up.
Alptekin K; Erkoç S; Göğüş AK; Kültür S; Mete L; Uçok A; Yazici KM
Psychiatry Res; 2005 Jun; 135(2):103-11. PubMed ID: 15923043
[TBL] [Abstract][Full Text] [Related]
39. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
40. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.
Rocca P; Crivelli B; Marino F; Mongini T; Portaleone F; Bogetto F
Compr Psychiatry; 2008; 49(2):170-6. PubMed ID: 18243890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
